greeksoup/ stock research
Stock research / United States / BNTX / Year to 31 December 2025

BioNTech SE (BNTX) annual results, year to 31 December 2025: revenue EUR 2,870 million, from the 20-F

BioNTech SE files a 20-F with the SEC once a year, in euros. In the year to 31 December 2025 it reported revenue of EUR 2,870 million ($3.2 billion at the year's average rate), up 4.3% on the year before. Its profit attributable to shareholders was EUR -1,136 million, and diluted earnings per share EUR -4.70.

Revenue
EUR 2,870 million
+4.3% on the year
FY2018FY2025
Operating margin
-49.0%
-47.8% a year earlier
FY2018FY2025
Net income
EUR -1,136 million
FY2018FY2025
Diluted EPS
EUR -4.70
FY2018FY2025

this yearthe year beforeIn euros as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2024Dec 2025
Revenue2,7512,870
Cost of sales541642
Research and development2,2542,105
Operating profit-1,314-1,405
Finance costs27.469.8
Profit before tax-678-1,051
Income tax-12.485.3
Profit for the year-665-1,136
Profit attributable to shareholders-665-1,136
Filing20-F20-F
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2024Dec 2025
Diluted EPS-2.77-4.70
Basic EPS-2.77-4.70
Filing20-F20-F

EUR per ordinary share, as filed.

Cash flow

Year toDec 2024Dec 2025
Cash from operations208456
Purchase of property, plant and equipment286175
Free cash flow-78.8281
Cash from investing-2,081-2,468
Cash from financing-45.9-52.9
Depreciation and amortisation298383
Dividends paid0.0n/a
Filing20-F20-F

EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2024Dec 2025
Funded by
Equity attributable to shareholders19,41119,224
Borrowings, as filed254267
Lease liabilities254230
Other liabilities2,6102,267
Total equity and liabilities22,53021,989
Owned
Property, plant and equipment9351,081
Goodwill381368
Cash and cash equivalents9,7627,675
Trade and other receivables1,464924
Inventories283111
Other assets9,70511,830
Total assets22,53021,989
Filing20-F20-F

EUR million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2024Dec 2025
Operating margin-47.8%-49.0%
Net margin-24.2%-39.6%
Free cash flow margin-2.9%9.8%
Return on year-end equity-3.4%-5.9%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2025, filed 30 July 2026: the filing. The figures are in euros as filed.